CME Group Cl A shows improving price performance, earning an upgrade to its IBD Relative Strength Rating from 78 to 82.

CME’s performance has remained even more impressive over the longer term. CME stock has surged 19.7% on a YTD basis and 36.4% over the past year, significantly outpacing KCE’s 1.9% dip in 2025 ...

Overall, CME Group revenues are forecasted to touch $5.97 billion in FY2024. Additionally, CME’s adjusted net income margin is likely to improve in the year, leading to an annual GAAP EPS of $9.75.

CME Group posts strong earnings on growing trading volumes and margins. Learn the risks, market opportunities, and why it's ...

What Happened: In a significant move reported in a Form 4 filing with the U.S. Securities and Exchange Commission on Thursday, Suskind purchased 532 shares of CME Group, demonstrating confidence in ...

Here is how CME Group (CME) and ACNB ... By taking a look at the stock's year-to-date performance in comparison to its Finance peers, we might be able to answer that question.

CME Group’s stock (NASDAQ NDAQ: CME) has lost 9% YTD, while the S&P500 is down 18% over the same period. Further, its current price of $209 per share is trading 14% below its fair value of $243 ...

CME Group vs S&P 500 Performance Over 2007-08 Financial Crisis. CME Group stock declined from levels of around $122 in October 2007 (the pre-crisis peak) to roughly $36 in March 2009 (as the ...

However, shares of the company have slipped nearly 5% from its 52-week high of $249.02. CME Group stock has gained 7.9% over the past three months, lagging behind the broader Dow Jones Industrials ...

CME Group's stock performance has been underwhelming compared to the market, with low growth expectations and negative sentiment from institutional investors. However, there are reasons to ...

CME Group Inc(NASDAQ:CME) recently announced a dividend of $1.1 per share, payable on 2023-09-27, with the ex-dividend date set for 2023-09-07. As investors look forward to this upcoming payment ...

CME’s performance has remained even more impressive over the longer term. CME stock has surged 19.7% on a YTD basis and 36.4% over the past year, significantly outpacing KCE’s 1.9% dip in 2025 ...